Teva Pharmaceutical Industries Ltd., TEVA today presented results
from a post hoc analysis of two pivotal Phase III clinical trials
showing that treatment with reslizumab reduced clinical asthma
exacerbations (CAEs) by 75 percent versus placebo in a subgroup of
patients with late onset asthma (diagnosed at 40 years of age and older)
with elevated blood eosinophils, who were inadequately controlled on
inhaled corticosteroids (ICS). Reslizumab is a humanized
anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for which Teva is
seeking approval in the treatment of asthma in patients with elevated
blood eosinophils who are inadequately controlled on an ICS-based
regimen. These results were presented as a late-breaking abstract at the
2015 ERS International Congress in Amsterdam.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in